DOH Issues Advisory on Underutilization of COVID-19 Antivirals
On Feb. 20, 2024, the Department of Health (DOH) issued an advisory regarding COVID-19 antiviral underutilization and changes in how to access the medications with their transition from U.S. government-managed purchase and distribution to the commercial market.
According to the advisory:
- Recent data from the National Institutes of Health (NIH) show that only 10% of individuals with COVID-19 who are at high risk for severe COVID-19 are treated.
- Individuals at high risk for severe COVID-19 include those aged 50 and older, those who are unvaccinated, and those with a range of health conditions including diabetes, heart disease and obesity.
- Antiviral therapy for COVID-19 infection reduces the risk of hospitalization and death in individuals at high risk of progression to severe disease from COVID-19.
- Oral antivirals remain active against current circulating strains of SARS-CoV-2, the virus causing COVID-19.
- COVID-19 oral antiviral treatments have transitioned from US government-managed purchase and distribution to the commercial market with changes in how patients can access medications.
- Several programs have been developed to ensure access to antiviral medications at low or no cost to patients (please see table [in advisory]).
- Home Test-to-Treat funded by the federal government offers evaluation and treatment regardless of insurance status.
Members are encouraged to read the advisory for information on how to access the antivirals and other resources available.
Contact: Amy Nelson, anelson@leadingageny.org, 518-867-8383 ext. 146